Medspas adding NAD+ IV therapy discover fast that their existing collaborating physician agreement was written for Botox and filler, not infusion protocols. That gap creates real liability exposure the moment your first NAD+ patient sits in the infusion chair.
- A collaborating physician agreement for NAD+ IV therapy must name IV/infusion scope explicitly – injectables-only language does not cover it.
- Amending an existing agreement is the fastest path for most medspas already under supervision; verdict: Buy.
- Telehealth-only supervision is a Skip for NAD+ IV therapy in states requiring in-person oversight for vascular access procedures.
- Good faith exams still apply before the first NAD+ infusion in states that require them for new modalities.
- US Medical Directors structures NAD+ IV therapy addendums separately from injectable scope to close the coverage gap.
Why this matters
NAD+ IV therapy isn't an injectable – it's an infusion, and most state boards treat vascular access and prolonged infusion differently from a five-second Botox injection. If your collaborating physician agreement only lists neuromodulators, fillers, and laser procedures, adding NAD+ without amending that document leaves your practice operating outside the scope your supervising physician actually agreed to.
A medical director for NAD+ IV therapy clinics reviews dosing protocols, infusion rates, and adverse reaction plans that a general aesthetics-focused agreement never anticipated. Skipping this step is the single most common gap found when medspas expand their menu in 2026.
Who this is for
This guide is for medspa owners, nurse practitioners, and RNs who already run injectables or body contouring under a collaborating physician and now want to add NAD+ IV therapy to the menu. It's also for solo NP-owned practices building their first agreement from scratch with IV services included on day one. If you're still deciding whether to offer NAD+ at all, this won't help – it assumes the service decision is made and the compliance work is next.
What to look for in a collaborating physician agreement for NAD+ IV therapy
Explicit infusion therapy scope language
An agreement that lists "aesthetic procedures" without naming IV or infusion therapy specifically does not cover NAD+. Boards distinguish between injection and infusion because infusion involves prolonged vascular access, variable flow rates, and a longer window for adverse reactions. Get the scope section rewritten to name NAD+ IV therapy by name, not by inference.
Dosing and protocol authority
NAD+ protocols vary widely – some clinics run 250mg over an hour, others push higher doses over 2 to 4 hours. Your agreement needs standing orders or protocols that specify who sets the dose, who can adjust the infusion rate mid-session, and what triggers a call to the collaborating physician.
State-specific supervision ratios and telehealth limits
Some states cap how many NPs or RNs one collaborating physician can oversee, and that ratio doesn't automatically expand when you add a new service line. Multi-state operators should check the telehealth collaborating rules before assuming remote supervision covers infusion-based services the same way it covers injectables.
Adverse reaction and emergency protocols specific to IV push
NAD+ pushed too fast causes chest tightness, flushing, and nausea in a meaningful share of patients – this is a documented, common reaction, not a rare edge case. The agreement needs a written protocol: stop the infusion, slow the rate, when to call 911, and how the incident gets documented in the chart.
Good faith exam requirements before the first infusion
States that require good faith exams for injectables generally extend that requirement to new modalities, including IV therapy. Confirm whether your state treats NAD+ as requiring a fresh exam or whether an existing exam on file covers the new service.
Liability coverage that names infusion therapy
Medical director liability policies written around injectables sometimes exclude IV therapy entirely. Check the coverage language before your first NAD+ patient, not after an incident.
Top picks for structuring the agreement
The default move: amend your existing agreement.
Most medspas already under a collaborating physician don't need a new relationship – they need the current document updated. Add an NAD+ IV therapy addendum with its own protocol section, dosing ranges, and adverse event language rather than folding it into the injectables clause. One clear number to check: does the amendment require re-signature from the physician, or just an addendum acknowledgment? Confirm which one your state board expects before treating your first patient. Review how to structure a collaborating physician agreement before drafting language yourself. Verdict: Buy.
The specialist add-on: a standalone NAD+ addendum.
Instead of amending the master agreement, some practices attach a separate, dated addendum specific to NAD+ IV therapy that can be updated or removed without touching the rest of the scope. This works well if you expect to test the service for 6 to 12 months before committing long-term. Verdict: Consider for practices piloting NAD+ before a full menu rollout.
The wildcard: cross-license with an IV hydration-focused director.
If your medspa already runs IV hydration alongside NAD+, a physician experienced with IV hydration clinics often has protocol language for both services ready to adapt, cutting drafting time. The tradeoff: you need a director who understands both the injectables side and the infusion side, which narrows the pool. Verdict: Consider for practices running a full infusion menu, not just a single NAD+ add-on.
The volume play: a bulk or group contract.
Multi-location medspas and franchise groups adding NAD+ across every site at once benefit from a single master agreement with location-specific addendums rather than negotiating five separate contracts. This scales well but takes longer to draft up front. Verdict: Buy for groups with 3+ locations, Skip for single-site solo practices where a simple amendment is faster.
The remote option: telehealth-only supervision.
Some states allow telehealth collaboration for certain aesthetic services, but IV therapy's vascular access component pushes many boards toward requiring in-person availability, at least for the initial good faith exam. Don't assume your existing telehealth arrangement automatically extends to infusion therapy. Verdict: Skip unless your state explicitly permits remote supervision for infusion-based services.
Get your agreement built for NAD+ IV therapy
Physician oversight structured for infusion protocols, not just injectables.
What to avoid
- Injectables-only boilerplate. An agreement that never mentions infusion, IV, or vascular access wasn't written with NAD+ in mind, no matter how comprehensive it looks otherwise.
- A physician with zero infusion experience. Someone who has only ever reviewed Botox charts may not catch a dosing error on an NAD+ protocol – ask directly about their infusion therapy background before signing anything.
- Skipping the good faith exam because "the patient already had one." A good faith exam for filler doesn't automatically satisfy the requirement for a new infusion-based service in states that require modality-specific exams.
Verdict comparison
| Structure | Best for | Drafting speed | Verdict |
|---|---|---|---|
| Amend existing agreement | Single-location, already supervised | Fast (1-2 weeks) | Buy |
| Standalone NAD+ addendum | Piloting the service | Fast | Consider |
| IV hydration crossover director | Full infusion menu | Moderate | Consider |
| Bulk/group contract | 3+ locations | Slower (multi-week) | Buy for groups |
| Telehealth-only supervision | Remote-first practices | Fast, but check state rules | Skip |
FAQ
What is a collaborating physician agreement for NAD+ IV therapy?
It’s a written agreement between a medspa and a supervising physician that specifically names IV infusion therapy, including NAD+ dosing protocols and adverse reaction procedures, as part of the practice’s covered scope. A generic injectables agreement does not automatically cover it.
Do medspas need a collaborating physician for NAD+ IV therapy?
In most states, yes – any provider ordering or administering IV infusions under a nurse practitioner or RN license needs physician oversight covering that specific service. Requirements vary by state, so check your board’s rules on infusion therapy specifically.
Can I add NAD+ IV therapy under my existing collaborating physician agreement?
Only if the agreement already names infusion or IV therapy in its scope section. If it only lists injectables, you need an amendment or addendum before treating patients with NAD+ in 2026.
Is a good faith exam required before the first NAD+ IV infusion?
States that require good faith exams for aesthetic services generally extend that requirement to new modalities like NAD+ IV therapy. An exam on file for injectables doesn’t always cover a new infusion service – verify with your state board.
Can telehealth collaboration cover NAD+ IV therapy?
Sometimes, but many boards require in-person supervision availability for infusion-based services because of the vascular access component. Don’t extend a telehealth injectables agreement to IV therapy without confirming your state allows it.
How long does it take to add NAD+ IV therapy to a collaborating physician agreement?
A straightforward amendment to an existing agreement typically takes 1-2 weeks. A new standalone agreement or a multi-location group contract takes longer, often several weeks, depending on how many locations and providers are involved.
What should the physician review before signing off on NAD+ IV therapy?
The physician should review dosing ranges, infusion rate protocols, adverse reaction procedures for chest tightness or flushing, and emergency escalation steps before agreeing to supervise NAD+ IV therapy specifically.
Does adding NAD+ IV therapy change medical director liability coverage?
It can. Some liability policies written around injectables exclude infusion therapy entirely, so confirm coverage extends to IV services before your first NAD+ patient in 2026.
One last thing
The detail most medspas miss isn't the paperwork – it's the infusion rate protocol. NAD+ pushed too fast is the number one cause of adverse reactions reported at infusion clinics, and a collaborating physician agreement without a specific rate-adjustment clause leaves your staff guessing mid-session. Get that one paragraph right and most of the rest of the compliance work falls into place.
Related guides
- How to verify a collaborating physician's license before signing
- How to audit your collaborating physician agreement for gaps
